2021 Media Partners & Associations
Looking to Set Up a Media Partnership?
We work with a variety of organizations and associations that share our interest in this industry. We come together to ensure our community have access to relevant information, news and services, and to spread the word about our event to people we believe it will be beneficial for. If you would like to discuss a media partnership, please get in contact:
Pharma Journalist is a paramount B2b online magazine platform exhibiting targeted and succinct information concerning the world of Pharmaceutical Industry therefore keeping a tab on the updated and latest updates and trends concerning the field.
Our widespread and market specific content write-ups cater to Industry professionals intending to keep pace with this dynamic and revolutionary industry. Articles like latest news, trends, analysis, market reports, press releases, whitepapers , case studies, etc, enable further insight as well as an in-depth interpretation of industry trends.
Our editorial staff is committed to disseminating concise facts and information to its readers and subscribers by collating credible information from known sources and decoding them in the form of innumerable content pieces. Ranging from objective facts to subjective, analytical studies enables a holistic view of the topics scouted for.
It is noteworthy that Pharma Journalist which is a product of Kellen Media also offers a plethora of online marketing services aiding companies and organizations to reach out to targeted audiences based on the geographical and demographic profiles ensuring enhanced reach and visibility garnered for their products or events paving way for accentuated brand awareness
Launched in June 2015, the BEAM Alliance (Biotech companies in Europe combating AntiMicrobial Resistance) Alliance is a strong Network of approx. 70 small and medium-sized European companies involved in developing innovative products and kits to tackle antimicrobial resistance (AMR), including small molecule antibiotics, biologics, products with a prophylaxis indication, microbiome-based and phage-based therapies, immune targeting therapies, anti-biofilm agents and medical devices including in vitro diagnostics.
BEAM collaborates with the existing community of stakeholders dedicated to implementing tangible strategies. BEAM gives its members a unique voice to propose and support policies and incentives in antimicrobial research and development in Europe. BEAM recommends bold incentives that warrant action by policymakers to stimulate much needed innovation.